hmec

XMD8-92 is an effective and specific BMK1/ERK5 inhibitor (Kd: 80 nM).

TRIA-662 (Nicotinamide Chloromethylate) is a niacin metabolite excreted via the urinary system.

Demethoxydeacetoxypseudolaric acid B analog has potent activities against HMEC-1, HL-60, A-549, MB-MDA-468, BEL-7402, HCT116, and Hela cells with IC50s ranging from 0.136 to 1.162 μM. and is semi-synthesized by efficient routines from Pseudolaric acid B.

Quininib is a selective antagonist of CysLTR1 and CysLTR2, with IC50 values of 1.2 and 52 μM, respectively, exhibiting anti-angiogenic and anti-tumour effects.

E70K is a compound that inhibits the interaction between the chemokine (C-X-C) ligand 8 (CXCL8) and glycosaminoglycans (GAGs) on cell membrane surfaces. It mimics a segment of the CXCL8 protein's GAG-binding region at the C-terminal end, incorporating a glutamate-to-lysine mutation at the 70th position. At a concentration of 50 nM, E70K notably reduces the attachment of primary human neutrophils to human umbilical vein endothelial cells (HUVECs). Moreover, it impedes the CXCL8-triggered movement of these neutrophils across HMEC-1 human microvascular endothelial cell layers within a concentration range of 1 to 1,000 nM.

Eutypenes I (Compound 9) inhibits the secretion of VEGF-A, hampers the activation of VEGFR, and disrupts its downstream Erk/Akt signaling pathway. It also suppresses the migration of HMEC-1 cells and demonstrates anti-angiogenic activity in a Sprague-Dawley rat model.